Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lutetium Lu 177 edotreotide by ITM Isotope Technologies Munich for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
Lutetium Lu 177 edotreotide is under clinical development by ITM Isotope Technologies Munich and currently in Phase III for Neuroendocrine...
ITM-91 by ITM Isotope Technologies Munich for Metastatic Renal Cell Carcinoma: Likelihood of Approval
ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Renal Cell Carcinoma....
ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval
ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer. According...
ITM-91 by ITM Isotope Technologies Munich for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According...
ITM-91 by ITM Isotope Technologies Munich for Solid Tumor: Likelihood of Approval
ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor. According to...
ITM-31 by ITM Isotope Technologies Munich for Glioblastoma Multiforme (GBM): Likelihood of Approval
ITM-31 is under clinical development by ITM Isotope Technologies Munich and currently in Phase I for Glioblastoma Multiforme (GBM). According...